Steven Brugger

Steve Brugger brings over 30 years of experience in the biotech and pharmaceutical industry to Affinivax. He most recently served as the Chief Executive Officer of Visterra, a private biotech company based in Cambridge, Mass. During his tenure at Visterra, Steve led the company in closing a Series A round of financing, advancing its lead antibody program toward IND, and establishing strategic partnerships with both Pfizer and the Bill & Melinda Gates Foundation. Prior to Visterra, Steve was the Chief Operating Officer at Momenta Pharmaceuticals. While at Momenta,

Steve held several leadership roles as the company grew from a private start-up to a successful public-traded biotechnology company. Prior to Momenta, Steve held various leadership and management positions at Millennium, Novartis, Ayerst, and Hoechst Pharmaceuticals. Steve received his BA in Biology from Susquehanna University and his MBA from the Rutgers Graduate School of Management.

Steven Brugger is the President and CEO at Affinivax, based in United States, North America. With a background in Biotechnology, Steven Brugger has a rich history of leadership and innovation.Steven Brugger studied MBA Business at Rutgers Business School Newark and New Brunswick. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.